This trial is testing whether lower ACT targets during percutaneous coronary intervention (PCI) is associated with lower rates of bleeding while having similar rates of ischemic events.
- Coronary Artery Disease
- Coronary Syndrome
- Anticoagulant-induced Bleeding
2 Primary · 1 Secondary · Reporting Duration: From date of randomization until the date of first documented stent thrombosis, assessed up to 30 days.
3 Treatment Groups
Medium ACT Target
1 of 3
High ACT Target
1 of 3
Low ACT Target
1 of 3
368 Total Participants · 3 Treatment Groups
Primary Treatment: Medium ACT Target · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What indications is High ACT Target commonly prescribed for?
"High ACT Target is commonly used for medical device treatment, however its efficacy in other contexts has also been observed. It can be taken to address sprains and heart conditions such as unstable angina pectoris or atrial fibrillation." - Anonymous Online Contributor
Are there any spaces still available for participants in this research endeavor?
"As of today, the clinical trial is actively seeking patients. Its initial posting was on February 8th 2019 and it underwent its most recent edit on 14th February 2022 according to the data available from clinicialtrials.gov." - Anonymous Online Contributor
What is the current estimated participant count for this medical research endeavor?
"Affirmative. According to clinicaltrials.gov, this experiment was initially posted back on February 8th 2019 and has been recently updated in February 14th 2022; it is currently looking for 546 patients conducted at a single site." - Anonymous Online Contributor
Has the FDA approved High ACT Target for release?
"With an optimistic assessment based on the Phase 2 classification, High ACT Target can be deemed moderately safe with a score of 2. It should be noted that while safety is supported by data, efficacy has yet to be clinically confirmed." - Anonymous Online Contributor
Is this the initial implementation of such a clinical trial?
"Initiated in 2006, High ACT Target has been subject to growing scrutiny and clinical trials since. The first such study was sponsored by Ash Access Technology and involved 415 participants, resulting in the drug's Phase 3 approval. Currently, 36 separate studies are underway across 197 cities spanning 21 countries." - Anonymous Online Contributor
Are there previous experiments that have explored the efficacy of High ACT Target?
"At the present time, there are 12 Phase 3 experiments and 36 active trials assessing High ACT Target. Of those studies, 367 sites have been chosen to host them; particularly in Sherbrooke, Quebec." - Anonymous Online Contributor